Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever

• Status: Completed
• Trial end date: 2019-07-31
• Target enrollment: 0
• Participant gender: All

Summary

Empirical antibiotic therapy has been known to reduce the mortality and morbidity rate in neutropenic fever. Until now, ceftazidime was the first line choice of neutropenic fever. However, resistance against ceftazidime has been reported. Several countries have reported cefepime in reducing fever and shorten the length of hospitalization better than ceftazidime. This study is aimed to compare the effectivity of ceftazidime and cefepime to reduce fever and to increase the absolute neutrophils count (ANC) in the first 72 hours.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indonesia University
• Treatments: Anti-Bacterial Agents; Cefepime; Ceftazidime

Criteria

Inclusion Criteria:

• children with leukemia aged 1 month to 18 years old undergoing chemotherapy

• having fever of ≥ 38,3 0C in axillar temperature

• ANC < 1000/mm3

• patients' parents or guardians must be willing to participate and willing to sign a written informed consent form

Exclusion Criteria:

• patients with a history of penicillin or cephalosporin allergy

• patients with kidney dysfunction